Drugs designed to strip amyloid beta out of the brain do not produce clinically meaningful benefits for people in the early stages of Alzheimer's disease, according to a new Cochrane review. The analysis pooled data from 17 clinical trials involving 20,342 participants, all of whom had mild cognitive impairment or mild dementia attributed to Alzheimer's. Reviewers reported that the effects on cognitive decline and dementia severity were either absent or trivial, sitting well below the accepted threshold for what counts as a minimum clinically important difference.
The finding cuts against a central assumption behind this class of drugs. High amyloid beta levels can be detected in the brain before symptoms appear, and the reasoning has been that removing the protein early, before the disease advances, would slow or prevent decline. Yet the trials in this review were conducted specifically in that early window, which supporters have argued is where the drugs should work best.
Against the negligible benefit, the review found an increased risk of bleeding and swelling in the brain. That trade-off matters for families weighing whether to pursue these treatments, since it means accepting a real safety risk in exchange for changes on cognitive tests too small to notice in daily life.
The review does not settle what role amyloid beta plays in Alzheimer's, and the source material is explicit that its contribution to disease progression remains uncertain. What it does suggest is that clearing the protein, on its own, has not translated into the benefit researchers hoped for - a result that will shape how the field allocates attention and funding to other lines of investigation.